Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24020908 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Francesca Lucca und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Cystic Fibrosis, Lung Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cystic fibrosis (CF) is characterized by a progressive decline in lung function, which may be further impaired by viral infections. CF is therefore considered a comorbidity of coronavirus disease 2019 (COVID-19), and SARS-CoV-2 vaccine prioritization has been proposed for patients with (pw)CF. Poor outcomes have been reported in lung transplant recipients (LTR) after SARS-CoV-2 infections. LTR have also displayed poor immunization against SARS-CoV-2 after mRNA-based BNT162b2 vaccination, especially in those undergoing immunosuppressive treatment, mostly those receiving mycophenolate mofetil (MMF) therapy. We aimed to determine here the immunogenicity and safety of the BNT162b2 vaccine in our cohort of 260 pwCF, including 18 LTR. Serum levels of neutralizing anti-SARS-CoV-2 IgG and IgA antibodies were quantified after the administration of two doses. PwCF displayed a vaccine-induced IgG and IgA antiviral response comparable with that seen in the general population. We also observed that the immunogenicity of the BNT162b2 vaccine was significantly impaired in the LTR subcohort, especially in patients undergoing MMF therapy. The BNT162b2 vaccine also caused minor adverse events as in the general population, mostly after administration of the second dose. Overall, our results justify the use of the BNT162b2 vaccine in pwCF and highlight the importance of a longitudinal assessment of the anti-SARS-CoV-2 IgG and IgA neutralizing antibody response to COVID-19 vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy.
- Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy.
- Unit of Pediatrics, S. Maria di Ca' Foncello Hospital, 31100 Treviso, Italy.
ORCID-Profile: Valentino Bezzerri, Elisa Danese, Debora Olioso, Christian Boni, Martina Montagnana, Mirco Ros, Giuseppe Lippi
Zitieren
APA
Lucca, F., Bezzerri, V., Danese, E., Olioso, D., Peserico, D., Boni, C., Cucchetto, G., Montagnana, M., Tridello, G., Meneghelli, I., Ros, M., Lippi, G., & Cipolli, M. (2023). Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24020908
Vancouver
Lucca F, Bezzerri V, Danese E, Olioso D, Peserico D, Boni C, et al. Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24020908
BibTeX
@article{Lucca2023,
author = {Lucca, Francesca and Bezzerri, Valentino and Danese, Elisa and Olioso, Debora and Peserico, Denise and Boni, Christian and Cucchetto, Giulia and Montagnana, Martina and Tridello, Gloria and Meneghelli, Ilaria and Ros, Mirco and Lippi, Giuseppe and Cipolli, Marco},
title = {Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24020908}
}
EUVIMED